A successful investor and life sciences entrepreneur, Brian Frenzel serves on the Board of Directors of SanBio, Inc., a regenerative medicine company.
Advances in medical technology have improved the quality of life and life expectancy for sufferers of neurodegenerative diseases such as Parkinson’s disease, multiple sclerosis, and spinal cord injury, as well as for patients who have had cerebral strokes. SanBio, Inc., in Mountain View, California, develops new therapies to help patients with these conditions to recover function and lead more comfortable lives. These therapies are designed to repair and regenerate damaged neuronal cells and tissues with the objective of reversing neurological damage and restoring normal function.
The core component of SanBio’s technology is the use of bone marrow stromal cells harvested from donors. When these cells are genetically manipulated and delivered to damaged tissue, they stimulate recovery. An important advantage of using donor bone marrow cells is that they are readily available and the cells from a single donor can be multiplied in cell culture to treat thousands of patients.
SanBio is developing products to treat cerebral stroke, spinal cord injury, Parkinson’s disease, multiple sclerosis, and traumatic brain injury. San Bio’s most advanced product, SB623, is undergoing human clinical trials in the United States to improve function in cerebral stroke patients.